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Fibroblast growth factor 19 (FGF19) is increasingly 
recognized as a key hormone regulating many functions. 
A recent publication by Luo et al. in Science Translational 
Medicine has advanced understanding of the diverse actions 
of FGF19 and has suggested how therapeutics with this 
protein may be optimized (1).
FGF19 in humans is a 24 kDa protein which is syntenic 
with FGF15 in rodents; both have similar tissue distribution 
and actions and are sometimes known as FGF15/19 (2). 
FGF15/19, together with FGF21 and FGF23, are members 
of the larger group of fibroblast growth factors and share the 
property of low heparin sulfate binding, which allows them 
to function as circulating endocrine molecules with effects 
on distant tissues. FGF15/19 has major effects regulating 
hepatic bile acid synthesis (3) and also acts on carbohydrate 
and lipid metabolism (4). FGF21 also has metabolic 
functions, and FGF23 is the key hormone regulating 
phosphate homeostasis. These effects are produced through 
FGF receptors (FGFR). FGF15/19 at physiological levels 
acts preferentially through FGFR4, which forms complexes 
with β-Klotho, and produces intracellular effects through 
kinase actions (2,5).
FGF19 is synthesized in the ileum in response to bile 
acid absorption. Bile acids bind to farnesoid X receptor 
(FXR) and potently activate transcription of FGF15 in 
mouse intestine (3) and FGF19 in human ileal explants 
[reviewed in (6)]. FGF19 enters the portal venous 
circulation and inhibits new bile acid synthesis in the liver 
by decreasing CYP7A1 activity, thus providing negative 
feedback. Serum FGF19 increases after meals (7) and is 
much lower in patients who have had ileal resection or 
with inflammation in Crohn’s disease (8-10). Impaired 
regulation of bile acid synthesis by FGF19 has been 
proposed to be a causative factor in the common disorder 
known as primary bile acid diarrhea or idiopathic bile acid 
malabsorption (8). Furthermore, obeticholic acid, a semi-
synthetic modified bile acid and a potent FXR agonist, 
stimulated FGF19 production and improved symptoms in 
these patients (11). A role for defective FGF15/19 in bile 
acid-induced diarrhea is further supported by evidence from 
mouse models with knock-out of the components of FGF15 
system (Fgf15, Fgfr4 and Klb) which have increased fecal 
bile acid loss, increased synthesis and a larger bile acid pool 
size.Additionally, severe diarrhea resulted in monkeys when 
FGF19 was neutralized with antibodies [reviewed in (6)]. 
Therapy to increase FGF19 actions seems to be a promising 
approach to treating this form of chronic diarrhea associated 
with excess bile acid production.
The metabolic actions of FGF19 also suggest therapeutic 
possibilities in obesity, diabetes and the metabolic syndrome 
(2,4,12). Obese subjects and those with nonalcoholic fatty 
liver (NAFLD) and/or metabolic syndrome may have 
lower median serum FGF19 levels (13), which increase 
rapidly after bariatric surgery (14). Obeticholic acid 
stimulates FGF19 and produced clinical and histological 
improvements in NAFLD patients (15). 
Importantly, FGF19 may be beneficial in cholestatic 
disorders. FGF19 is secreted by the human gallbladder 
into bile and transcripts are greatly increased in the livers 
of patients with extrahepatic cholestasis with increased 
amounts of protein being found in blood (16). It has been 
suggested that the role of this induced FGF19 is to inhibit 
bile acid synthesis by CYP7A1 in an autocrine/paracrine 
fashion so preventing accumulation of toxic levels of bile 
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acids. After liver resection in mice, FGF15/19 was shown 
to modulate bile acid levels preventing toxic injury and 
improving survival. Liver growth, DNA synthesis and cell 
proliferation were increased (17). 
Such proliferative actions have led to concern about the 
possible relevance of FGF19 for liver neoplasia in humans (18). 
Indeed, FGF19 and FGFR4 are co-expressed in a proportion 
of human liver, lung and colon tumors (19). Expression of 
FGF19 was associated with recurrence and a relatively poor 
prognosis in hepatocellular carcinoma (20). In a transgenic 
mouse model, overexpression of human FGF19 in skeletal 
muscle (to levels many hundred times those normally 
found) resulted in increased hepatocyte proliferation and 
hepatocellular carcinomas, and increased proliferation also 
occurred after injection of supraphysiological amounts 
(30 μg/mouse) of recombinant FGF19 (21). 
To address these potential concerns, Luo and colleagues 
have modified the FGF19 molecule, and in an elegant series 
of experiments, show this is nontumorigenic but retains the 
beneficial actions on bile acid metabolism and in cholestasis. 
The modified FGF19, known as M70, has a five amino-acid 
deletion and three amino-acids substituted at the N-terminal 
region. M70 showed none of the liver tumor-inducing 
activity of FGF19 when these forms were expressed in mice 
via an adenoviral vector for 24 weeks. It should be noted that 
this system gives serum levels of FGF19 or M70 which were 
around 2 μg/mL, 10,000-fold higher than usual human serum 
levels (~0.2 ng/mL) (7,8). Expression of markers including 
glutamine synthase, Ki-67, α-fetoprotein and cyclins was 
increased by FGF19 but not by M70 in this model.
M70 retained the ability of FGF19 to inhibit bile 
acid synthesis through decreased activity of the key rate-
limiting enzyme CYP7A1. This was confirmed over a 
range of doses, both in human primary hepatocytes and 
in mice injected with either protein. It was shown in two 
mouse models of cholestasis (one extrahepatic and one 
intrahepatic) to be protective when it was given for 5 days 
before bile duct ligation and for 4 additional days. Necrotic 
areas in the liver and markers of damage were reduced by 
both FGF19 and M70. Similar benefits were found in the 
α-naphthylisothiocyanate model of intrahepatic cholestasis. 
M70 was shown to normalize hepatic transporter transcripts 
which were deranged in the cholestasis models.
The M70 protein was further validated in phase I 
studies in normal human volunteers. In a randomized, 
double-blind, placebo-controlled trial, subcutaneous 
injections of M70 (3 mg/d) or placebo were given for 
7 days. M70 suppressed serum levels of 7α-hydroxy-4-
cholesten-3-one (C4) by over 95%, indicating marked 
suppression of new bile acid synthesis and this effect 
persisted for 24 h after dosing. Post-prandial serum bile 
acid levels were decreased. No serious adverse events or 
laboratory abnormalities occurred.
The implications of this translational study are far-
reaching. A single daily dose of M70 appears safe and is 
effective at suppressing bile acid synthesis in humans. 
Important benefits were shown in mouse models of 
cholestasis. These findings suggest that injections of M70 
(and perhaps native FGF19) could have therapeutic roles 
in adverse conditions of excessive bile acid production 
including, but not limited to, intrahepatic and extrahepatic 
cholestatic conditions, but also in intestinal disorders of bile 
acid diarrhea, either primary or that secondary to Crohn’s 
disease. Particularly in this later condition, where ileum 
has been resected or is diseased, FXR agonists such as 
obeticholic acid may not be able to stimulate ileal FGF19 
production sufficiently (10,11); injected replacement 
therapy may be preferable.
Any concerns about FGF19 promoting hepatocellular 
carcinoma in humans may not turn out to be realistic at 
physiological levels. The relationships between FXR and 
hepatocarcinogenesis are complex (22), and the critical 
interactions of FGF19 with FGFR4 appear different in 
humans to those in mice (23). However the development 
of M70, lacking any liver tumor-promoting effects in mice, 
appears to be a major advance which should lead to further 
clinical investigation and hopefully important therapeutic 
benefits.
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